TORONTO, Aug. 27, 2015 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced Health Canada's approval of its application for the generic version of PrVesicare® for the treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urinary urgency and urinary frequency. Teva Canada is the sole generic supplier of this treatment in Canada.
PrVesicare® had annual sales of approximately $38 million in Canada, based on IMS Brogan sales data as of July 2015. PrTeva-Solifenacin is available immediately in pharmacies across Canada.
"The symptoms of overactive bladder in adults can significantly affect the quality of life of the people affected by this common condition," said Doug Sommerville, Senior Vice President and General Manager, Teva Canada Limited. "Not only does overactive bladder affect social, psychological and physical aspects of those who suffer from it, the medications that are used to treat the condition can be costly. Teva Canada is very pleased to be able to offer Canadians and third party payors some relief by providing significant cost savings with this less expensive, bioequivalent option."
According to the Canadian Continence Foundation, nearly one in five Canadians over the age of 35 suffers from overactive bladder.i OAB occurs when a large muscle in the bladder, called the detrusor, contracts more often than normal, causing a person to feel a sudden and sometimes overwhelming urge to urinate, even when the bladder isn't full.i Unfortunately, as a result of the personal nature of the symptoms, many sufferers are reluctant to discuss their condition with their healthcare provider or family member, and as a result OAB remains underreported.ii
About Teva Canada Limited
Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare solutions for 50 years, with nearly 200,000iii prescriptions filled with our products every day. Originally Novopharm Limited, Teva Canada specializes in the development, production and marketing of high-quality generic prescription pharmaceuticals and through our branded division, Teva Canada Innovation, focuses on a diverse line of innovative products in a variety of therapeutic areas. Teva Canada employs more than 1,300 individuals, markets more than 400iv products in Canada and is a subsidiary of Teva Pharmaceutical Industries Ltd., the world's largest generic drug maker. For more information, visit: www.tevacanada.com or www.tevamakesmedicines.ca.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com.
___________________________________________
i Canadian Continence Foundation. Overactive Bladder vs. SUI. http://www.canadiancontinence.ca/EN/overactive-bladder-vs-sui.php. Accessed April 27, 2015.
ii Abrams, P., et. al. Overactive Bladder significantly affects quality of life. American Journal of Managed Care. 2000 Jul;6(11 Suppl):S580-90.
iii IMS Compuscript TRx MAT July 2015.
iv IMS CD&H MAT July 2015.
SOURCE Teva Canada Limited
PR Contact: Teva Pharmaceutical Industries Ltd., Denise Bradley, Sr. Vice President, Global Corporate Reputation, Teva Pharmaceuticals, p. +1.215.591.8974, [email protected]
Share this article